The most commonly reported tadalafil adverse reactions include headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and pain in a limb. Current U.S. labeling provides actual clinical-trial percentages, but those figures differ by dose, regimen, indication and study population.
That distinction matters because tadalafil can be used as needed for erectile dysfunction or once daily in different labeled contexts. A headache rate measured in men taking 20 mg as needed should not be merged with a rate from a 5 mg once-daily BPH study and presented as one universal 'tadalafil side-effect percentage.'
This page focuses on common treatment-emergent reactions and how to interpret the label data. The broader safety framework belongs on the tadalafil side-effects hub, while uncommon urgent events such as prolonged erection, sudden vision loss or sudden hearing changes belong on the serious tadalafil side-effects page.
Across current CIALIS labeling, headache, dyspepsia, back pain and myalgia repeatedly appear in controlled-trial safety tables. Nasal congestion, flushing and pain in a limb also appear among the commonly reported reactions in the as-needed ED studies.
Other treatment-emergent events appear in particular once-daily studies, including nasopharyngitis, upper respiratory tract infection, cough, diarrhea and gastroesophageal reflux disease. Their presence in a trial table does not mean that every event has the same mechanistic relationship to tadalafil.
For this reason, it is more accurate to start with the label data and then interpret the pattern rather than reducing tadalafil tolerability to one short symptom list.
| Reaction | Where it appears prominently | Broad interpretation |
|---|---|---|
| Headache | PRN ED, daily ED, BPH/ED+BPH | One of the most consistently reported tadalafil reactions |
| Dyspepsia | PRN ED, daily ED, BPH/ED+BPH | Indigestion / upper gastrointestinal discomfort |
| Back pain | PRN ED, daily ED, BPH/ED+BPH | Characteristic tadalafil-associated musculoskeletal reaction |
| Myalgia | PRN ED, daily ED, BPH/ED+BPH | Muscle pain |
| Nasal congestion | PRN ED and daily ED tables | Nasal stuffiness or congestion |
| Flushing | PRN ED and daily ED tables | Vascular flushing sensation |
| Pain in limb / extremity | PRN ED, daily ED and BPH/ED+BPH tables | Pain reported in an arm or leg |
The word 'common' can be misleading if it is treated as one universal numerical category. In the current CIALIS highlights, the most common adverse reactions are described as those reported in at least 2% of treated patients, but individual clinical-trial tables use their own reporting thresholds.
For example, the main as-needed ED table and the 12-week once-daily ED table report treatment-emergent reactions meeting a ≥2% threshold and occurring more frequently with tadalafil than placebo. The BPH and ED/BPH once-daily table uses a lower ≥1% threshold.
That difference in table design is one reason percentages should be compared within a study context rather than ranked across unrelated tables.
| Label table | Population / regimen | Reporting threshold |
|---|---|---|
| As-needed ED | PRN tadalafil | ≥2% in specified tadalafil groups and more frequent than placebo |
| Once-daily ED | 2.5 mg or 5 mg daily | ≥2% and more frequent than placebo |
| Once-daily BPH / ED+BPH | 5 mg daily | ≥1% and more frequent than placebo |
The primary placebo-controlled as-needed ED studies provide the clearest dose-stratified adverse-reaction table in the label. The trials included placebo and tadalafil 5 mg, 10 mg and 20 mg groups, although the table's inclusion criterion is based on reactions reported at the specified threshold in the main 10 mg or 20 mg treatment groups.
Headache and dyspepsia show the largest numerical differences across the tadalafil strengths. Back pain, myalgia, nasal congestion, flushing and pain in a limb occurred less often but still met the label table's reporting criteria.
These are group-level trial percentages, not individualized probabilities and not a recommendation to choose or avoid a particular strength.
| Adverse reaction | Placebo (N=476) | Tadalafil 5 mg (N=151) | Tadalafil 10 mg (N=394) | Tadalafil 20 mg (N=635) |
|---|---|---|---|---|
| Headache | 5% | 11% | 11% | 15% |
| Dyspepsia | 1% | 4% | 8% | 10% |
| Back pain | 3% | 3% | 5% | 6% |
| Myalgia | 1% | 1% | 4% | 3% |
| Nasal congestion | 1% | 2% | 3% | 3% |
| Flushing | 1% | 2% | 3% | 3% |
| Pain in limb | 1% | 1% | 3% | 3% |
The 12-week once-daily ED studies used 2.5 mg and 5 mg tadalafil and produced a different adverse-reaction profile from the as-needed table. The individual doses are lower, administration is repeated every day, and the study population and exposure pattern are not identical to PRN treatment.
Headache was reported in 5% of placebo patients, 3% of the 2.5 mg group and 6% of the 5 mg group. Dyspepsia occurred in 2%, 4% and 5%, respectively, while back pain occurred in 1%, 3% and 3%.
The fact that some placebo percentages exceed one active-dose percentage is another reason not to assume every symptom occurring after tadalafil was necessarily caused by the medication.
| Adverse reaction | Placebo (N=248) | Tadalafil 2.5 mg (N=196) | Tadalafil 5 mg (N=304) |
|---|---|---|---|
| Headache | 5% | 3% | 6% |
| Dyspepsia | 2% | 4% | 5% |
| Nasopharyngitis | 4% | 4% | 3% |
| Back pain | 1% | 3% | 3% |
| Upper respiratory tract infection | 1% | 3% | 3% |
| Flushing | 1% | 1% | 3% |
| Myalgia | 1% | 2% | 2% |
| Cough | 0% | 4% | 2% |
| Diarrhea | 0% | 1% | 2% |
| Nasal congestion | 0% | 2% | 2% |
| Pain in extremity | 0% | 1% | 2% |
| Urinary tract infection | 0% | 2% | 0% |
| Gastroesophageal reflux disease | 0% | 2% | 1% |
| Abdominal pain | 0% | 2% | 1% |
Current CIALIS labeling separately reports safety data from three 12-week studies of 5 mg once-daily treatment: two in men with BPH and one in men with both ED and BPH. These participants were older on average than those in the main ED studies, and the table uses a ≥1% reporting threshold rather than ≥2%.
Headache occurred in 4.1% of tadalafil-treated patients versus 2.3% with placebo. Dyspepsia and back pain each occurred in 2.4% of the tadalafil group, while nasopharyngitis, diarrhea, pain in an extremity, myalgia and dizziness appeared at lower rates.
These percentages should remain attached to the BPH/ED+BPH study context rather than being averaged with ED-only trials.
| Adverse reaction | Placebo (N=576) | Tadalafil 5 mg (N=581) |
|---|---|---|
| Headache | 2.3% | 4.1% |
| Dyspepsia | 0.2% | 2.4% |
| Back pain | 1.4% | 2.4% |
| Nasopharyngitis | 1.6% | 2.1% |
| Diarrhea | 1.0% | 1.4% |
| Pain in extremity | 0.0% | 1.4% |
| Myalgia | 0.3% | 1.2% |
| Dizziness | 0.5% | 1.0% |
Putting all tadalafil adverse-reaction percentages into one average would create a number that does not correspond to any actual clinical trial. PRN ED, once-daily ED and BPH/ED+BPH studies differ in dose, frequency, age distribution, inclusion criteria and table-reporting thresholds.
Current labeling itself cautions that adverse-reaction rates observed in one clinical trial cannot be directly compared with rates in another clinical trial and may not reflect rates observed in practice. The safest interpretation is therefore study-specific.
A cross-regimen clinical comparison belongs on the daily vs as-needed tadalafil page; this page uses the regimen distinction only to interpret adverse-event data correctly.
| Difference | PRN ED | Daily ED | Daily BPH / ED+BPH |
|---|---|---|---|
| Typical studied strengths in main table | 5, 10 and 20 mg | 2.5 and 5 mg | 5 mg |
| Dosing framework | As needed | Once daily | Once daily |
| Main table reporting threshold | ≥2% criterion | ≥2% | ≥1% |
| Population | ED | ED | BPH or ED+BPH |
| Should percentages be mathematically pooled? | No | No | No |
Headache is the most prominent common tadalafil adverse reaction across several labeling contexts. In the as-needed ED table, it occurred in 11% of the 5 mg and 10 mg groups and 15% of the 20 mg group, compared with 5% of placebo patients.
The daily ED data illustrate why this should not be turned into a simple dose-to-headache formula: headache occurred in 5% of placebo patients, 3% with 2.5 mg tadalafil and 6% with 5 mg. Clinical-trial percentages contain background symptoms as well as treatment-associated differences.
A headache that is severe, unusual, persistent or accompanied by other concerning symptoms deserves clinical assessment rather than being dismissed simply because headache is a known common tadalafil reaction.
| Headache context | Placebo | Tadalafil |
|---|---|---|
| PRN ED — 5 mg | 5% | 11% |
| PRN ED — 10 mg | 5% | 11% |
| PRN ED — 20 mg | 5% | 15% |
| Daily ED — 2.5 mg | 5% | 3% |
| Daily ED — 5 mg | 5% | 6% |
| BPH / ED+BPH — 5 mg daily | 2.3% | 4.1% |
Dyspepsia is the clinical label term commonly interpreted as indigestion or upper gastrointestinal discomfort. It is one of the clearest tadalafil-associated reactions in the as-needed ED trials, increasing from 1% with placebo to 4%, 8% and 10% across the 5 mg, 10 mg and 20 mg groups.
The once-daily studies show lower absolute rates in their own populations: 5 mg daily for ED produced a 5% rate in the 12-week trials, while 5 mg daily in the BPH/ED+BPH studies produced a 2.4% rate.
Other gastrointestinal events such as gastroesophageal reflux disease, abdominal discomfort, nausea or diarrhea appear in particular tadalafil studies, but they should not all be collapsed into the dyspepsia percentage.
| Dyspepsia context | Placebo | Tadalafil |
|---|---|---|
| PRN ED — 5 mg | 1% | 4% |
| PRN ED — 10 mg | 1% | 8% |
| PRN ED — 20 mg | 1% | 10% |
| Daily ED — 2.5 mg | 2% | 4% |
| Daily ED — 5 mg | 2% | 5% |
| BPH / ED+BPH — 5 mg daily | 0.2% | 2.4% |
Back pain and myalgia are particularly distinctive tadalafil adverse reactions because the label describes their timing and physical pattern in detail. In clinical pharmacology studies they generally appeared about 12 to 24 hours after dosing and typically resolved within 48 hours.
The discomfort was described as diffuse bilateral lower-lumbar, gluteal, thigh or thoracolumbar muscular discomfort and could be worsened by lying down. Most reports were mild or moderate, and diagnostic testing in the studies did not show medically significant evidence of inflammation, muscle injury or renal damage.
The characteristic pattern is useful context, but it is not a diagnostic test. Severe, persistent or otherwise concerning back or muscle pain should not automatically be attributed to tadalafil simply because these reactions are listed in the prescribing information.
| Back pain / myalgia feature | Current label context |
|---|---|
| Typical reported onset | About 12–24 hours after dosing |
| Typical reported resolution | Usually within 48 hours |
| Reported distribution | Lower back, gluteal, thigh or thoracolumbar muscular areas |
| Typical severity | Generally mild or moderate |
| Severe back pain | Reported with low frequency |
| Does the pattern prove tadalafil caused every episode? | No |
Back pain occurred in 3% of placebo patients and 3%, 5% and 6% of tadalafil 5 mg, 10 mg and 20 mg groups in the main PRN ED trials. Myalgia occurred in 1% of placebo patients and 1%, 4% and 3% of the corresponding tadalafil groups.
In once-daily treatment, the numerical pattern differs. The 12-week daily ED studies reported back pain in 3% of both tadalafil groups and myalgia in 2%, while the BPH/ED+BPH studies reported back pain in 2.4% and myalgia in 1.2% with tadalafil 5 mg.
These data reinforce that adverse-reaction frequency is not a fixed property of the drug independent of study context.
| Study context | Back pain | Myalgia |
|---|---|---|
| PRN ED — placebo | 3% | 1% |
| PRN ED — tadalafil 5 mg | 3% | 1% |
| PRN ED — tadalafil 10 mg | 5% | 4% |
| PRN ED — tadalafil 20 mg | 6% | 3% |
| Daily ED — tadalafil 2.5 mg | 3% | 2% |
| Daily ED — tadalafil 5 mg | 3% | 2% |
| BPH / ED+BPH — tadalafil 5 mg | 2.4% | 1.2% |
Nasal congestion and flushing are common tadalafil reactions associated with its broader smooth-muscle and vascular pharmacology. In the as-needed ED studies, each occurred in approximately 2% to 3% of tadalafil-treated groups depending on strength, compared with 0% to 1% in relevant placebo groups.
Once-daily ED studies also reported both events, although the percentages again depended on dose and study duration. Their presence should not be interpreted as proof of clinically important hypotension.
Marked dizziness, fainting or symptoms suggesting significant blood-pressure lowering belong to a different safety and interaction context and are better evaluated through the broader tadalafil safety overview and interaction pages.
| Reaction | PRN ED placebo | PRN 5 mg | PRN 10 mg | PRN 20 mg |
|---|---|---|---|---|
| Nasal congestion | 1% | 2% | 3% | 3% |
| Flushing | 1% | 2% | 3% | 3% |
Pain in a limb appears in the primary as-needed ED adverse-reaction table, where it was reported in 1% of placebo patients, 1% with tadalafil 5 mg and 3% with both 10 mg and 20 mg. Daily trial tables use the related term 'pain in extremity.'
The BPH/ED+BPH studies reported pain in an extremity in 1.4% of tadalafil 5 mg patients and none of the placebo group. These terminology differences are another reason to preserve the wording and study context of the source table rather than creating an artificial pooled category.
Pain in an extremity should also not be assumed to have the same characteristic timing pattern described specifically for tadalafil-associated back pain and myalgia.
| Context | Placebo | Tadalafil |
|---|---|---|
| PRN ED — 5 mg | 1% | 1% |
| PRN ED — 10 mg | 1% | 3% |
| PRN ED — 20 mg | 1% | 3% |
| Daily ED — 5 mg | 0% | 2% |
| BPH / ED+BPH — 5 mg daily | 0.0% | 1.4% |
The daily ED studies list events such as nasopharyngitis, upper respiratory tract infection, cough, diarrhea and urinary tract infection because they met the numerical reporting criteria used for those trials. Inclusion in an adverse-reaction table does not mean each event has an equally clear pharmacologic mechanism linking it to tadalafil.
This is especially visible when placebo and active-treatment rates are similar or when a reaction appears in one dose group but not another. Clinical-trial tables are designed to report observed treatment-emergent events under predefined rules, not to prove mechanistic causation event by event.
For users, the practical value is to recognize the repeated core tadalafil pattern — especially headache, dyspepsia and musculoskeletal symptoms — while reading the rest of the table with appropriate context.
| Treatment-emergent event | Interpretive caution |
|---|---|
| Nasopharyngitis | Appears in daily trial tables but is not uniquely specific to tadalafil |
| Upper respiratory tract infection | Observed treatment-emergent event; causality is not established by table inclusion alone |
| Cough | Rates differed across treatment groups without a simple dose-response pattern |
| Urinary tract infection | Appeared in one daily dose group in the 12-week table |
| Diarrhea | Reported in daily trial contexts and at lower frequency in BPH studies |
Some PRN adverse reactions show a broadly higher numerical frequency at higher strengths. Dyspepsia, for example, rose from 4% with 5 mg to 8% with 10 mg and 10% with 20 mg, while headache was 11%, 11% and 15%, respectively.
Other reactions do not follow a perfectly monotonic pattern. Myalgia was reported in 1% with 5 mg, 4% with 10 mg and 3% with 20 mg, demonstrating why it is inaccurate to say that every side effect simply rises in a straight line with dose.
Trial tables describe population patterns rather than individualized dosing decisions. The clinical role of each strength belongs on the tadalafil dosage page.
| Claim | Supported? |
|---|---|
| Some common reactions are numerically more frequent at higher PRN strengths | Yes |
| Every tadalafil side effect rises linearly with dose | No |
| 20 mg guarantees more side effects in every individual | No |
| A side-effect table determines the right personal dose | No |
Treatment discontinuation provides another view of tolerability, but it also must be kept within study context. In the primary as-needed ED trials, 3.1% of patients treated with tadalafil 10 mg or 20 mg discontinued because of adverse events compared with 1.4% of placebo-treated patients.
Across placebo-controlled once-daily ED trials, discontinuation because of adverse events occurred in 4.1% of tadalafil-treated patients versus 2.8% with placebo. In the BPH/ED+BPH trials, the corresponding rates were 3.6% and 1.6%.
These percentages should not be ranked as evidence that one regimen is categorically more tolerable than another, because the underlying studies differed in population, treatment duration and clinical context.
| Study context | Tadalafil discontinuation due to adverse events | Placebo |
|---|---|---|
| As-needed ED — 10 or 20 mg primary studies | 3.1% | 1.4% |
| Once-daily ED trials | 4.1% | 2.8% |
| Once-daily BPH / ED+BPH trials | 3.6% | 1.6% |
Calling a reaction common does not mean that every episode should simply be ignored. Severity, persistence, timing, associated symptoms and the individual's other medications or health conditions can change how a symptom should be interpreted.
A mild headache, transient indigestion or the characteristic temporary back-pain pattern is different from a severe or unusual symptom, fainting, a major allergic reaction or another event that does not fit the expected tolerability profile. Concerning symptoms should be medically assessed rather than self-classified solely from a frequency table.
Urgent or rare warning signs are intentionally not expanded here. Those events and their label-specific action language belong on the serious tadalafil side-effects page.
| Situation | Broad interpretation |
|---|---|
| Mild familiar common reaction | May be monitored if otherwise uncomplicated |
| Persistent or difficult-to-tolerate reaction | Discuss with a healthcare professional |
| Severe or unusual symptom | Seek clinical assessment |
| Urgent warning sign | Use the serious-event guidance rather than treating it as a routine common effect |
Cialis and FDA-approved generic tadalafil products contain the same active ingredient, so the core tadalafil adverse-reaction profile is shared. Headache, dyspepsia, back pain and other established tadalafil reactions are not unique to the Cialis brand name.
Finished products can differ in inactive ingredients, appearance and manufacturer-specific labeling. That means a suspected product-specific or hypersensitivity reaction should still be evaluated in the context of the exact medicine dispensed rather than assuming every formulation is compositionally identical.
For broader branded-product information, see the Cialis page.
| Feature | CIALIS | FDA-approved generic tadalafil |
|---|---|---|
| Active ingredient | Tadalafil | Tadalafil |
| Core common tadalafil reactions | Shared | Shared |
| Inactive ingredients necessarily identical | No | No |
| Specific product label still relevant | Yes | Yes |
Frequency and seriousness are different concepts. Headache or dyspepsia may occur relatively often without being among tadalafil's most serious risks, while an uncommon event can deserve urgent attention because of its potential consequence.
This page therefore does not use common-reaction tables to estimate the frequency of prolonged erection, sudden vision loss, sudden hearing loss or other serious postmarketing events. Those events come from different sections of the labeling and require different evidence interpretation.
For the complete safety hierarchy, begin with the master tadalafil side-effects guide and use the serious-reactions page for urgent-event recognition.
| Category | Examples | Where it belongs |
|---|---|---|
| Common treatment-emergent reactions | Headache, dyspepsia, back pain, myalgia | This page |
| Serious or urgent events | Prolonged erection, sudden vision or hearing changes | Serious side effects |
| Warnings / precautions | Cardiovascular or hypotension-related risk contexts | Warnings |
Headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and pain in a limb are the core common tadalafil adverse reactions highlighted in current U.S. labeling. Their observed frequencies vary meaningfully with regimen, dose and study population.
PRN ED, daily ED and BPH/ED+BPH percentages should remain separate because they come from different clinical-trial contexts and even use different reporting thresholds. A single pooled tadalafil side-effect percentage would therefore be methodologically misleading.
Back pain and myalgia have an especially well-described tadalafil pattern, generally beginning 12 to 24 hours after dosing and typically resolving within 48 hours in clinical pharmacology studies. Serious or rare reactions, however, require a different evidence and action framework and belong on the dedicated serious-side-effects page.
Current U.S. labeling identifies headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and pain in a limb among the most common tadalafil adverse reactions.
Headache is one of the most consistently reported reactions. In the primary as-needed ED studies, headache occurred in 11% of tadalafil 5 mg and 10 mg groups and 15% of the 20 mg group, compared with 5% with placebo.
In the primary placebo-controlled as-needed ED studies reported in current U.S. labeling, headache occurred in 15% of the tadalafil 20 mg group compared with 5% of placebo patients. That percentage applies to that study context and is not an individual prediction.
Yes. Dyspepsia, commonly described as indigestion, is an established tadalafil adverse reaction. In the as-needed ED trials it was reported in 4% with 5 mg, 8% with 10 mg and 10% with 20 mg, compared with 1% with placebo.
Yes. Back pain is a recognized tadalafil reaction. In clinical pharmacology studies, tadalafil-associated back pain or myalgia generally appeared about 12 to 24 hours after dosing and typically resolved within 48 hours.
Current labeling documents a characteristic back-pain and myalgia pattern but does not provide a simple consumer-level mechanism that explains every case. The symptoms were generally muscular in distribution, and clinical-study testing did not show medically significant underlying muscle, inflammatory or renal injury.
In clinical pharmacology studies described in current labeling, back pain or myalgia generally occurred 12 to 24 hours after dosing and typically resolved within 48 hours. An individual episode can differ, especially if pain is severe or has another cause.
Yes. Myalgia is an established tadalafil adverse reaction and appears in both as-needed and once-daily clinical-trial tables.
Yes. Nasal congestion is listed among common tadalafil reactions. In the primary PRN ED trials it occurred in 2% to 3% of tadalafil-treated groups compared with 1% with placebo.
Yes. Flushing is a recognized common adverse reaction. In the primary as-needed ED trials it occurred in 2% to 3% of tadalafil groups compared with 1% with placebo.
Some reactions were numerically more frequent at higher as-needed strengths, particularly headache and dyspepsia, but not every adverse reaction increased in a perfectly linear pattern. Tablet strength alone cannot predict an individual's tolerability.
The percentages should not be compared as if they came from one trial. Daily 5 mg and PRN 20 mg were studied under different dosing patterns and in different clinical settings, so direct rate comparisons can be misleading.
The core reaction types overlap, but the observed frequencies differ. Current labeling reports separate adverse-reaction tables for PRN ED, daily ED and daily BPH or ED/BPH treatment.
Different sources may be quoting different doses, regimens, indications or clinical studies. A reliable comparison should identify whether the percentage comes from PRN ED, daily ED, BPH/ED+BPH or another study population.
Diarrhea appears in once-daily tadalafil clinical-trial tables, including the BPH/ED+BPH studies. Its reported frequency depends on the study context and is lower than the major common reactions such as headache.
Dizziness was reported in the BPH/ED+BPH once-daily studies, where it occurred in 1.0% of tadalafil 5 mg patients versus 0.5% with placebo. Dizziness can also matter in blood-pressure and drug-interaction contexts.
No. In the controlled studies summarized in current labeling, discontinuation because of adverse events occurred in a minority of participants. The exact percentage differed by regimen and study population.
Cialis and FDA-approved generic tadalafil contain the same active ingredient and share the core tadalafil adverse-reaction profile. Inactive ingredients and product-specific labeling can differ.
A common reaction deserves clinical attention when it is severe, persistent, worsening, difficult to tolerate or otherwise unusual. Serious warning signs should not be treated as routine common side effects and require the action specified in the serious-event guidance.
No. Common clinical-trial adverse-reaction percentages and uncommon serious or postmarketing events are different evidence categories. Serious reactions such as prolonged erection or sudden vision or hearing changes are handled separately in the prescribing information.